Given the role of RIPK1 kinase in driving the progression of NASH in both mouse models and human patients, we next examined whether RIPK1 activation can be seen in Senp1f/f;Alb-Cre mice using p-S166 RIPK1 (activation biomarker of RIPK134–36) immunostaining and immunoblotting. The gene discussed is ALB; the disease is metabolic dysfunction-associated steatohepatitis.